Delhi High Court Directs Meesho to Remove Alleged Counterfeit Sun Pharma Sunscreen Listings

New Delhi: The Delhi High Court has ordered the e-commerce platform Meesho to take down listings of allegedly counterfeit sunscreen products of Sun Pharmaceutical Industries Ltd., granting interim relief in a plea filed by the pharmaceutical company.

Justice Anup Jairam Bhambhani passed an ex-parte interim order directing Meesho to remove specific URLs of products claimed to be fake versions of Sun Pharma’s Belo Photostable and Photostable Gold sunscreens. The court also issued notices to Meesho and the manufacturers named in the petition, seeking their responses.

Sun Pharma told the court that none of its genuine sunscreen products are available or sold on Meesho. Despite this, the platform allegedly hosts counterfeit versions bearing its brand names. The company submitted a list of URLs of the disputed listings and argued that the sale of such unlicensed and fake products risks damaging its brand reputation and the consumer trust it has built over many years.

The pharmaceutical major further contended that Meesho, as an e-commerce marketplace, bears liability to ensure counterfeit goods are not sold on its platform and must promptly take down such listings upon being notified. The court took note of the list provided by Sun Pharma and ordered the immediate removal of the identified URLs.

The order comes amid growing concerns over counterfeit products on online marketplaces in India. Sun Pharma’s plea highlights questions about the extent of intermediary liability for e-commerce platforms regarding third-party sellers offering allegedly fake pharmaceutical and personal-care items. Consumer safety and brand protection issues were also raised in the submissions.

Reports in regional media, including Esakal, similarly noted the court’s directive requiring Meesho to delist the alleged counterfeit Sun Pharmaceuticals sunscreen products and advised online shoppers to exercise caution when purchasing health and beauty items.

Market observers, including the X account @Sharemarketinf, described the development as potentially negative for near-term sentiment around Meesho, citing concerns related to counterfeit-product compliance and marketplace oversight, while noting that legal proceedings remain ongoing.

As of the latest available reports, Meesho and the manufacturers have been issued notices and are expected to file their responses. The matter is set for further hearing. No final determination has been made on the allegations of counterfeiting, and the interim order is limited to the takedown of the specified listings pending further proceedings.

Related Posts

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

The issue came up for discussions during the visit of Commerce Secretary Rajesh Agarwal to Buenos Aires this week. Argentina has committed to reduce barriers to facilitate the entry of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

ICT Mumbai to host official launch of RasayanAI, bringing AI-powered drug discovery to researchers

ICT Mumbai to host official launch of RasayanAI, bringing AI-powered drug discovery to researchers